SingleGrowth Hormone

MK-677 25mg

Orally active non-peptide ghrelin receptor agonist investigated for pulsing growth hormone and elevating systemic IGF-1 concentrations.

Mechanism

Selectively binds and activates the pituitary and hypothalamic growth hormone secretagogue receptor type 1a (GHS-R1a), mimicking endogenous ghrelin to augment pulsatile growth hormone secretion and elevate downstream circulating IGF-1 levels.

Dosing

Historical human clinical literature documents an initial investigative oral dose ranging from 5 mg to 10 mg administered once daily.

Reconstitution

As an orally bioavailable solid capsule or pre-dissolved solution, this compound requires zero bacteriostatic water reconstitution.

Storage

Store solid capsule units in an airtight container at controlled room temperature shielded from ambient moisture, excessive heat, and direct light exposure.

Mix & measure MK-677 25mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure MK-677 25mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration—

Draw volume—

On the syringe—

Total doses in vial: —

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Dose-Ranging / Intro	5–10 mg (1× daily)	Oral solid / 1 capsule (or 0.2–0.4 mL at 25 mg/mL)
Standard Trial Cohort	25 mg (1× daily)	Oral solid / 1 capsule (or 1.0 mL at 25 mg/mL)
Provocative Testing	Single oral dose	Oral solid / trial-specific protocol

Reconstitution Steps

1
Verify that the reference material is supplied in an intact oral dosage form, such as standardized solid capsules or an analytical liquid suspension.
2
Do not introduce bacteriostatic water or attempt parenteral reconstitution, as this non-peptide small molecule is formulated exclusively for oral ingestion.
3
Inspect the supplier-provided analytical Certificate of Analysis to confirm chemical identity, strength, and raw purity before handling.
4
Retain the compound in its original airtight enclosure alongside a desiccant pack to avert moisture-induced degradation.
5
Record the intended laboratory testing mass to ensure consistency throughout the evaluation timeframe.

Supplies Needed

Peptide Vial

Supplies standardized oral capsules or liquid ibutamoren for laboratory research without requiring reconstitution.

Insulin Syringes (U-100)

Not utilized for administration; graduated oral dosing syringes may optionally be used for liquid preparations.

Bacteriostatic Water

Not required, as the chemical is orally active and does not undergo aqueous reconstitution.

Alcohol Swabs

Utilized exclusively for general bench surface disinfection rather than parenteral site preparation.

Why researchers study it

Pulsatile GH and circulating IGF-1 elevation

Fat-free mass and nitrogen retention research

Sleep architecture and nocturnal GH profile analysis

Appetite modulation and ghrelin pathway dynamics

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

MK-677, clinically designated as ibutamoren, is an orally bioavailable non-peptide secretagogue designed to trigger endogenous growth hormone release. Originally synthesized to circumvent the requirement for parenteral injection typical of peptide-based GH secretagogues, it selectively targets the ghrelin receptor to provoke episodic endocrine output. Throughout clinical exploration, investigators evaluated the compound across settings of catabolic wasting, frailty in aging cohorts, and somatopause. While administration reliably amplified circulating somatotropin and insulin-like growth factor 1, subsequent phase trials demonstrated equivocal results regarding functional physical performance, leading to the cessation of formal therapeutic drug development programs. In contemporary laboratory models, MK-677 remains a reference tool for probing the somatotropic axis, appetite modulation pathways, and sleep architecture. Researchers should account for downstream secondary alterations in carbohydrate metabolism, as sustained secretagogue activity characteristically impacts peripheral insulin sensitivity.

References

1.Nass et al., Ann Intern Med, 2008 — Effects of oral ghrelin mimetic on body composition and clinical outcomes in older adults
2.Copinschi et al., J Clin Endocrinol Metab, 1996 — Seven-day treatment with oral MK-677 in normal young men and GH pulsatility
3.Sevigny et al., Neurology, 2008 — 12-month double-blind RCT of MK-677 in patients with mild-to-moderate Alzheimer's disease
4.Chapman et al., J Clin Endocrinol Metab, 1996 — Stimulation of the GH/IGF-1 axis in healthy elderly subjects by oral MK-677
5.Svensson et al., J Clin Endocrinol Metab, 1998 — Two-month treatment with oral MK-677 in obese subjects on body composition and energy expenditure